Chimeric Therapeutics has initiated a strategic review to maximize shareholder value. The company reported A$0.8 million in cash at the end of the June 2026 quarter. An additional A$2.27 million was secured in July.
The review will explore options including partnerships, licensing agreements, and potential mergers. This initiative aims to secure the funding necessary to sustain the company's clinical programs.
Interim data from the CHM CDH17 trial for gastrointestinal cancers showed tumor shrinkage of up to 40%. The ADVENT-AML trial for acute myeloid leukemia demonstrated a 60% complete response rate.